NCT05769205

Brief Summary

Role of multi paramrtric MRI and MRI perfusion in indetermint ovarian lesions by using ORADS MRI

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
25

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Mar 2023

Typical duration for not_applicable

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 26, 2023

Completed
3 days until next milestone

Study Start

First participant enrolled

March 1, 2023

Completed
14 days until next milestone

First Posted

Study publicly available on registry

March 15, 2023

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2025

Completed
9 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2025

Completed
Last Updated

March 15, 2023

Status Verified

February 1, 2023

Enrollment Period

2 years

First QC Date

February 26, 2023

Last Update Submit

March 3, 2023

Conditions

Ovarian Neoplasms

Outcome Measures

Primary Outcomes (1)

  • MRI in ovarian tumors

    Role of parametric MRI in determint ovarian lesions by using ORADS MRI

    2 years

Study Arms (1)

female with ovarian masses

EXPERIMENTAL

MRI with contrast according to the kidney function test of the patients

Device: MRI

Interventions

MRIDEVICE

MRI with contrast

female with ovarian masses

Eligibility Criteria

Sexfemale(Gender-based eligibility)
Gender Eligibility DetailsOvaries lesions
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may not qualify if:

  • females with known benign ovarian masses

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Patel RK, Garg A, Dixit R, Gandhi G, Khurana N. The role of "penumbra sign" and diffusion-weighted imaging in adnexal masses: do they provide a clue in differentiating tubo-ovarian abscess from ovarian malignancy? Pol J Radiol. 2021 Dec 15;86:e661-e671. doi: 10.5114/pjr.2021.111986. eCollection 2021.

    PMID: 35059059BACKGROUND

MeSH Terms

Conditions

Ovarian Neoplasms

Condition Hierarchy (Ancestors)

Endocrine Gland NeoplasmsNeoplasms by SiteNeoplasmsOvarian DiseasesAdnexal DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital Neoplasms, FemaleUrogenital NeoplasmsGenital DiseasesEndocrine System DiseasesGonadal Disorders

Central Study Contacts

Maryam Farouk Sayed

CONTACT

01064353498Faroukmariam54@gmail.com

Mostafa Hashem

CONTACT

hashemradiol@yahoo.com

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Model Details: females with ovarian masses
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assiut university

Study Record Dates

First Submitted

February 26, 2023

First Posted

March 15, 2023

Study Start

March 1, 2023

Primary Completion

March 1, 2025

Study Completion

December 1, 2025

Last Updated

March 15, 2023

Record last verified: 2023-02